相似文献
1
In vivo synergism of roxithromycin (RU 965) and interferon against Toxoplasma gondii.
Antimicrob Agents Chemother. 1987 Feb;31(2):346-8. doi: 10.1128/AAC.31.2.346.
2
Activity of roxithromycin against Toxoplasma gondii in murine models.
J Antimicrob Chemother. 1987 Nov;20 Suppl B:69-74. doi: 10.1093/jac/20.suppl_b.69.
3
Activity of roxithromycin (RU 28965), a macrolide, against Toxoplasma gondii infection in mice.
Antimicrob Agents Chemother. 1986 Aug;30(2):323-4. doi: 10.1128/AAC.30.2.323.
4
In vivo and in vitro activity of roxithromycin against Toxoplasma gondii in mice.
Eur J Clin Microbiol. 1987 Aug;6(4):479-81. doi: 10.1007/BF02013115.
5
In-vitro and in-vivo activities of roxithromycin in combination with pyrimethamine or sulphadiazine against Toxoplasma gondii.
J Antimicrob Chemother. 1995 Jun;35(6):821-32. doi: 10.1093/jac/35.6.823.
6
Effect of roxithromycin on acute toxoplasmosis in mice.
Antimicrob Agents Chemother. 1987 Jul;31(7):1147-9. doi: 10.1128/AAC.31.7.1147.
7
Experimental evaluation of roxithromycin combined with dapsone or sulphamethoxazole on Pneumocystis carinii and Toxoplasma gondii dual infections in a rat model.
J Antimicrob Chemother. 1998 Mar;41 Suppl B:57-62. doi: 10.1093/jac/41.suppl_2.57.
8
Synergistic activity of azithromycin and gamma interferon in murine toxoplasmosis.
Antimicrob Agents Chemother. 1991 Aug;35(8):1672-3. doi: 10.1128/AAC.35.8.1672.
9
Nonionic block copolymers potentiate activities of drugs for treatment of infections with Toxoplasma gondii.
Antimicrob Agents Chemother. 1995 Dec;39(12):2696-701. doi: 10.1128/AAC.39.12.2696.
10
Activity of spiramycin against Toxoplasma gondii in vitro, in experimental infections and in human infection.
J Antimicrob Chemother. 1988 Jul;22 Suppl B:87-92. doi: 10.1093/jac/22.supplement_b.87.
引用本文的文献
1
The ketolide antibiotics HMR 3647 and HMR 3004 are active against Toxoplasma gondii in vitro and in murine models of infection.
Antimicrob Agents Chemother. 1997 Oct;41(10):2137-40. doi: 10.1128/AAC.41.10.2137.
2
In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii.
Antimicrob Agents Chemother. 1988 Apr;32(4):524-9. doi: 10.1128/AAC.32.4.524.
3
Current recommendations and future prospects in the treatment of toxoplasmosis.
Drugs. 1989 Dec;38(6):973-87. doi: 10.2165/00003495-198938060-00008.
4
New directions for macrolide antibiotics: structural modifications and in vitro activity.
Antimicrob Agents Chemother. 1989 Sep;33(9):1413-8. doi: 10.1128/AAC.33.9.1413.
5
Animal models in interferon research: some current trends.
Experientia. 1989 Jun 15;45(6):558-62. doi: 10.1007/BF01990506.
6
Activity of gamma interferon in combination with pyrimethamine or clindamycin in treatment of murine toxoplasmosis.
Eur J Clin Microbiol Infect Dis. 1990 May;9(5):358-60. doi: 10.1007/BF01973746.
7
Effect of clindamycin on pneumonia from reactivation of Toxoplasma gondii infection in mice.
Antimicrob Agents Chemother. 1991 Apr;35(4):780-2. doi: 10.1128/AAC.35.4.780.
8
Role of gamma interferon in Toxoplasma gondii infection.
Eur J Clin Microbiol Infect Dis. 1991 Feb;10(2):58-67. doi: 10.1007/BF01964408.
9
Comparative activity of macrolides against Toxoplasma gondii demonstrating utility of an in vitro microassay.
Antimicrob Agents Chemother. 1991 May;35(5):903-9. doi: 10.1128/AAC.35.5.903.
10
In vivo activity of the macrolide antibiotics azithromycin, roxithromycin and spiramycin against Toxoplasma gondii.
Eur J Clin Microbiol Infect Dis. 1991 Jun;10(6):519-24. doi: 10.1007/BF01963942.
本文引用的文献
1
Effect of murine interferon gamma on murine toxoplasmosis.
J Infect Dis. 1984 Dec;150(6):961-2. doi: 10.1093/infdis/150.6.961.
2
Inhibition of growth of Toxoplasma gondii in cultured fibroblasts by human recombinant gamma interferon.
Infect Immun. 1984 May;44(2):211-6. doi: 10.1128/iai.44.2.211-216.1984.
3
Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity.
J Exp Med. 1983 Sep 1;158(3):670-89. doi: 10.1084/jem.158.3.670.
4
Assessment of therapy for pneumocystis carinii pneumonia. PCP Therapy Project Group.
Am J Med. 1984 Mar;76(3):501-8. doi: 10.1016/0002-9343(84)90670-3.
5
Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome.
Ann Intern Med. 1984 Apr;100(4):495-9. doi: 10.7326/0003-4819-100-4-495.
6
Interferon: protection of cells infected with an intracellular protozoan (Toxoplasma gondii).
Science. 1968 Aug 23;161(3843):804-6. doi: 10.1126/science.161.3843.804.
7
Activation of neonatal and adult human macrophages by alpha, beta, and gamma interferons.
Infect Immun. 1985 Aug;49(2):351-6. doi: 10.1128/iai.49.2.351-356.1985.
8
In vivo recombinant interleukin 2 administration enhances survival against a lethal challenge with Toxoplasma gondii.
J Immunol. 1985 Dec;135(6):4160-3.
Zotero 插件